Central Serous Chorioretinopathy: Multimodal Imaging and Management Options

Prashanth G. Iyer, Stephen G. Schwartz, Jonathan F. Russell, and Harry W. Flynn Jr.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA

Correspondence should be addressed to Stephen G. Schwartz; sschwartz2@med.miami.edu

Received 5 May 2020; Revised 25 July 2020; Accepted 29 July 2020; Published 14 August 2020

Copyright © 2020 Prashanth G. Iyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Central serous chorioretinopathy (CSCR) is an idiopathic maculopathy characterized by thickened choroid, retinal pigment epithelial detachment, and variable subretinal fluid. CSCR predominantly affects young men, with risk factors including corticosteroid use, the type A behavior pattern, and psychological stress. While usually self-limited with a good visual prognosis, recurrent and persistent CSCR can lead to outer retinal and/or retinal pigment epithelial atrophy, choroidal neovascularization, and visual loss. This article reviews current multimodal imaging and treatment options, which include observation, mineralocorticoid receptor antagonists, thermal laser photocoagulation, and off-label photodynamic therapy with verteporfin.

1. Introduction

Central serous chorioretinopathy (CSCR) is a macular disorder thought to be due to alterations of the choroidal vasculature that overwhelm the ability of the retinal pigment epithelial (RPE) to dehydrate the subretinal space, with consequent accumulation of subretinal fluid. [1–3] Thickened choroid, RPE detachments, and variable subretinal fluid are cardinal features of CSCR. Patients may be asymptomatic or may complain of central scotoma, metamorphopsia, dyschromatopsia, and micropsia [4–6].

CSCR generally affects individuals between ages 30 and 50 years, with a predominance for men [7–11]. CSCR is most commonly seen in Asian and Caucasian patients [8]. Other risk factors include corticosteroid exposure, the type A behavior pattern (including a preponderance of a competitive drive, a sense of urgency, an aggressive nature, and a hostile temperament), psychological stress, Helicobacter pylori infection, use of phosphodiesterase 5 inhibitors, exogenous testosterone supplementation, obstructive sleep apnea, pregnancy, and some endocrine disorders [6, 11–19].

2. Clinical Features

Patients with acute CSCR typically present with clear and well-demarcated subretinal fluid. There is typically a smooth pigment epithelial detachment (PED) underlying the subretinal fluid, although the PED can be small and challenging to identify with biomicroscopy alone. The clinical course of CSCR is usually self-limited, with spontaneous resolution of subretinal fluid and restoration of visual acuity by three months [20]. The presence of turbid subretinal fluid and/or blood should alert the physician to the possibility of another diagnosis, including idiopathic choroidal neovascularization (CNV), exudative age-related macular degeneration, or polypoidal choroidal vasculopathy.

Some patients with CSCR will have a persistent or recurrent course beyond three months. Chronic CSCR can involve multifocal or diffuse RPE disruption and atrophy throughout the posterior pole, potentially causing severe visual loss [8]. RPE atrophy, along with outer retinal atrophy, secondary CNV, cystoid macular edema (CME), and choriocapillaris atrophy are causes of permanent visual loss [20] [21].
3. Imaging Modalities

3.1. Fluorescein Angiography. Fluorescein angiography (FA) can reveal various patterns in acute CSCR including focal leakage (sometimes called expansile dot) in the majority of cases (Figure 1) and a smokestack pattern in 10-20% of patients (Figure 2) [22].

Chronic CSCR may show multiple areas of mottled hyperfluorescence, indicating widespread patchy RPE dysfunction and/or atrophy [23]. FA can also detect the presence of secondary CNV.

3.2. Indocyanine Green Angiography. Indocyanine green angiography (ICGA) is another dye-based test that can detect
impaired choroidal circulation in CSCR, including choroidal hypoperfusion, delays in choroidal circulation, and hyperfluorescence corresponding to areas of choroidal hyperpermeability [24, 25].

3.3. Fundus Autofluorescence. Fundus autofluorescence (FAF) detects the endogenous fluorophores found in lipofuscin of the RPE cells, providing information regarding the health of the RPE [26, 27]. FAF patterns in acute CSCR may include confluent or granular hypoautofluorescence signifying loss of RPE cells and hyperautofluorescence representing accumulation of unphagocytized photoreceptor outer segments [28]. In chronic CSCR, there is multifocal or diffuse mottled hypoautofluorescence representing atrophy of the RPE. There can be areas of hyperautofluorescence. Descending tracts, also known as "guttering", (Figure 3) with increased and decreased autofluorescence may be seen [28, 29].

3.4. Optical Coherence Tomography. Optical coherence tomography (OCT) allows for rapid noninvasive identification of PED, CME, subretinal fluid, and other structural abnormalities (Figure 4). In addition, enhanced depth imaging OCT can detect increased choroidal thickness, which is characteristic of CSCR [30] (Figure 5). CSCR can be described in the spectrum of pachychoroid diseases, which share similar features of choroidal thickening and retinal pigment epithelial changes. [21, 31–33] The exact clinical significance of the different pachychoroid disorders with respect to treatment outcomes is uncertain and still under investigation [34].

3.5. Optical Coherence Tomography Angiography. Optical coherence tomography angiography (OCT-A) is a noninvasive, non-dye-based technique of angiography that can identify vascular flow in the different layers of the retina and choroid. OCT-A in CSCR can detect choroidal and choriocapillaris deficits, underlying CNV, and simultaneously
includes B-scans that may feature PED, subretinal fluid, CME, and outer retinal and/or RPE atrophy [35–37].

4. Management

4.1. Observation. The majority of patients with CSCR will have spontaneous resolution of subretinal fluid with recovery of vision. Observation is the first-line therapy for most patients who have had symptoms for less than about three months [5, 21] (Figures 6 and 7). The use of exogenous corticosteroids should be reduced or discontinued if possible. Occasionally, treatment can be initiated sooner for patients requiring more rapid improvement in vision for occupational or other needs.

4.2. Thermal Laser Photocoagulation. Thermal laser photocoagulation is a well-established option for treating CSCR by directly applying argon laser to a leaking site seen on FA and/or ICGA (Figures 8 and 9). Thermal laser photocoagulation has been reported to decrease subretinal fluid and improve visual acuity [38]. However, long-term visual outcomes have not been reported to improve significantly with argon laser treatment [39, 40]. While most studies reported no differences in recurrence rates associated with laser photocoagulation, there are a few studies that reported lower rates of recurrence in laser-treated patients [41–44]. Complications of thermal laser photocoagulation include scar formation and secondary CNV. Given the potential for scarring, argon laser is most appropriate for extrafoveal leaking sites [42].

Subthreshold micropulse laser was initially described by Bandello and colleagues. In their pilot study, five patients with chronic CSCR were treated and had complete subretinal fluid resorption without recurrence; follow-up data and subsequent case studies have been promising [45–47].

4.3. Photodynamic Therapy. Off-label photodynamic therapy (PDT) with verteporfin (Visudyne, Bausch + Lomb, Bridgewater, NJ) was first described in a case series of 15 patients with chronic CSCR. Complete resolution of subretinal fluid occurred in 12 of the 15 patients [48]. PDT has been reported effective in resolving subretinal fluid and improving visual acuity [48–50]. Complications associated with PDT include secondary CNV, choriocapillaris hypoperfusion, and RPE damage [51]. In an effort to reduce complications, low dose verteporfin and lower fluence PDT have been reported effective with lower risks of adverse effects [52, 53]. Half-dose PDT has been reported to reduce subretinal fluid compared to argon laser in CSCR; however, visual acuity outcomes were similar in both groups [40] (Figures 10–12). The authors are anecdotally aware of, but have no personal experience with, the use of PDT in pediatric patients.

4.4. Eplerenone and Spironolactone. Eplerenone and spironolactone are two mineralocorticoid receptor (MR) antagonists that are increasingly used in the off-label treatment of CSCR. One hypothesis for the etiology of CSCR is inappropriate activation of MR by glucocorticoids; of note, corticosterone induces choroidal dilation,
Figure 7: Central serous chorioretinopathy of the left eye. A 56-year-old male was observed for 3 years with worsening of metamorphopsia. (a) Fundus photography showed pigment irregularities and clumping over a pigment epithelial detachment (PED). (b) Fundus autofluorescence showed hypoautofluorescent changes surrounding the PED with granular hyperautofluorescence centrally. (c) Early-phase fluorescein angiography (FA) revealed faint pinpoint leakage and staining of the PED. (d) Early-phase indocyanine green angiography (ICGA) showed blockage due to the PED. (e, f) Late-phase FA and ICGA showed macular leakage. (g) Optical coherence tomography (OCT) showed a PED but no subretinal fluid. (h) One year later, OCT showed worsening of the PED and new subretinal fluid.
Figure 8: Continued.
hyperpermeability, and egress of fluid across the RPE into the subretinal space [54]. Spironolactone is a nonselective antagonist of the aldosterone receptor. Its effects of blocking the aldosterone receptor are hypothesized to decrease choroidal hyperpermeability from off-target binding of corticosteroids. Spironolactone has multiple effects on estrogens and androgens that can result in unwanted side effects in male patients such as gynecomastia, decreased libido, and erectile dysfunction [55–57].

Eplerenone is a newer, more selective aldosterone antagonist that binds to the MR and less to the other steroid receptors. Eplerenone has a 10- to 20-fold lower affinity to MR, and a 100- to 1000-fold lower affinity to the other steroid receptors than spironolactone, resulting in fewer side effects [57, 58]. In general, both MR antagonists are prone to hyperkalemia and potassium levels should be monitored [55]. The authors have no personal experience with the use of MR antagonists in pregnancy or in pediatric patients.

Bousquet et al. conducted a prospective, nonrandomized study of 13 patients with CSCR symptomatic for at least four months. These patients were treated with 25 mg of oral eplerenone daily for one week, followed by 50 mg daily for 1-3 months. Treatment with eplerenone was associated with significant improvements in central macular thickness, subretinal fluid, and visual acuity [59]. The authors followed up with a prospective, randomized, double-masked, placebo-controlled study of 16 patients randomized to receive 50 mg of spironolactone or placebo daily for 30 days. There was a significant reduction of subretinal fluid and subfoveal thickness in the treatment arm compared to placebo; however, no significant changes in best-corrected visual acuity were reported [60]. Herold et al. reported another prospective, nonrandomized study in 18 patients with chronic CSCR evaluating spironolactone 25 mg twice daily for 12 weeks. They reported improvements in subretinal fluid, central macular thickness, and visual acuity [61] (Figure 13).
Figure 9: Chronic central serous chorioretinopathy treated with thermal photocoagulation. A 17-year old male presented with blurred vision of the right eye for nine months. Visual acuity was 20/50 in the right eye. (a) Fundus photography showed pigment changes and subretinal fluid in the right eye. (b) Fundus autofluorescence showed hyperautofluorescence of the macula, corresponding to the subretinal fluid seen clinically. (c, d) Early-phase fluorescein angiography (FA) and indocyanine green angiography (ICGA) showed focal hyperfluorescence corresponding to the inferior edge of the fluid seen clinically. (e) Late-phase FA showed leakage in the inferior macula, noted by the yellow arrow. (f) Late-phase ICGA confirmed the leakage, noted by the yellow arrow. Thermal photocoagulation was chosen because of the young age and extrafoveal focal leakage. Yellow arrows indicate where thermal laser was applied. (g, h) Optical coherence tomography before (g) and one month after (h) thermal photocoagulation showed decrease in subretinal fluid (measured in μm) and improvement in central macular thickness. Visual acuity improved to 20/40+. The patient was then lost to follow-up.
4.5. Anti-vascular Endothelial Growth Factor Therapy. Anti-vascular endothelial growth factor (anti-VEGF) therapy is mainly used for chronic CSCR with secondary CNV (Figures 14 and 15). In cases without CNV, there is no evidence of elevated VEGF levels in plasma or aqueous, suggesting that anti-VEGF agents would be ineffective for the treatment of acute or chronic CSCR [62]. However, a few case series have reported variable efficacy using anti-VEGF agents for patients with chronic CSCR and no apparent CNV [63–65].

5. Conclusions

Acute CSCR is often self-limiting, so treatment of CSCR is generally not indicated except when symptoms persist for more than about 3 months. Some patients, especially monocular patients or patients with specific occupational needs, may benefit from earlier intervention. Chronic, nonresolving CSCR has no widely accepted and definitive treatment, due to the paucity of head-to-head clinical trials. In such cases, the authors prefer to use combined
Figure 11: Chronic central serous chorioretinopathy of the right eye treated with reduced fluence photodynamic therapy (PDT). A 49-year-old female presented with blurred vision in the right eye. Visual acuity was 20/50. (a) Fundus photography showed pigmentary changes of the right eye. (b) Fundus autofluorescence showed hypoautofluorescence at the macula. (c, d) Early-phase fluorescein angiography (FA) and indocyanine green angiography (ICGA) showed hyperfluorescence. (e, f) Late-phase FA and ICGA showed leakage in the inferior macula. (g) Optical coherence tomography prior to and (h) after half-fluence PDT showed improvement of subretinal fluid. Visual acuity improved to 20/25.
Figure 12: Continued.
FA and ICGA to identify extrafoveal sites of leakage that might be amenable to thermal photocoagulation, which is safe to use in almost all patients, including pregnant patients and in pediatric patients.

If there is no focal extrafoveal leak on angiography, options other than thermal photocoagulation include reduced fluence PDT and/or MR antagonists. This is typically an individualized decision. Some patients may be more willing to take a long-term systemic medication rather than undergo PDT with its required period of sunlight avoidance; other patients may prefer the reverse. Figure 16 summarizes the treatment options in CSCR.

Figure 12: Chronic central serous chorioretinopathy of the left eye treated with both thermal laser photocoagulation and half-fluence photodynamic therapy (PDT). A 42-year-old female presented with blurred vision for two years. (a–d) Images at baseline. (a) Fundus photography showed pigmentary changes around a pigment epithelial detachment (PED). (b) Early-phase fluorescein angiography (FA) showed leakage in the fovea as well as slightly superotemporal. (c) Late-phase FA showed increased leakage; the superotemporal lesion is noted by the yellow arrow. (d) Optical coherence tomography (OCT) showed a large subfoveal PED. The patient was initially treated with thermal photocoagulation to the superotemporal lesion (yellow arrow in (c)), so as to spare the fovea. (e) Following thermal photocoagulation, the clinical appearance did not change. (f) Early-phase FA and (g) late-phase FA showed improvement of the treated superotemporal lesion but persistent leakage of the untreated subfoveal PED. (h) OCT showed no change in the subfoveal PED (noted by the blue arrow in (g)). The patient then underwent half-fluence PDT (blue arrow in (g)). (i) One month later, OCT showed resolution of the pigment epithelial defect. Visual acuity improved from 20/30 to 20/20.

Figure 13: Central serous chorioretinopathy treated with eplerenone. A 44-year-old Hispanic male presented with distortion in left eye although visual acuity was 20/20. He reported symptoms for three months. (a) Optical coherence tomography (OCT) confirmed subretinal fluid. The patient was started on eplerenone 25 mg daily. (b) One month after starting treatment, OCT showed resolution of the subretinal fluid. Subjectively, the patient reported improvement.
Figure 14: Chronic central serous chorioretinopathy of the right eye with secondary choroidal neovascularization (CNV). A 53-year old female with chronic central serous chorioretinopathy presented with worsening subretinal fluid. Using swept source optical coherence tomography angiography (SS-OCTA – PLEX Elite 9000, Carl Zeiss Meditec, Dublin, CA) 6×6 scans were performed; shown is the slab between the retinal pigment epithelium (RPE) and Bruch’s membrane. (a) En face angiography showed the presence of type 1 choroidal neovascularization (CNV). (b) En face structural imaging showed the RPE elevation due to underlying CNV. (c) B-scan demonstrated subretinal fluid. The presence of a pigment epithelial detachment was seen, with increased flow (green) within the detachment indicating increased choroidal flow in the presence of CNV. The sclerochoroidal junction (yellow dashes) was highlighted to demonstrate the thick choroid. OCT prior to (d) and after (e) anti-vascular endothelial growth factor injections showed improvement of subretinal fluid.

Figure 15: Chronic central serous chorioretinopathy of the right eye with secondary choroidal neovascularization (CNV). A 59-year old male with a history of inhaled triamcinolone use for asthma presented with worsening vision. Using swept source optical coherence tomography angiography (SS-OCTA – PLEX Elite 9000, Carl Zeiss Meditec, Dublin, CA), 6×6 scans were analyzed; shown is the slab between the retinal pigment epithelium (RPE) and Bruch’s membrane. (a) En face angiography showed the presence of type 1 choroidal neovascularization. (b) En face structural imaging showed RPE elevation causing shadowing. (c) B-scan demonstrated cystoid macular edema, with increased flow (green) indicating increased choroidal flow in the presence of CNV. The sclerochoroidal junction (yellow dashes) was highlighted to demonstrate the thick choroid. (d, e) OCT prior to and after anti-vascular endothelial growth factor injections showed improvement of intraretinal fluid and hyperreflective material.
**Conflicts of Interest**

None of the authors have any conflicts of interest.

**Acknowledgments**

This study is partly supported by the NIH Center Core Grant P30EY014801 and by an unrestricted grant from the Research to Prevent Blindness.

**References**

[1] A. Pryds, B. Sander, and M. Larsen, “Characterization of subretinal fluid leakage in central serous chorioretinopathy,” Investigative Ophthalmology & Visual Science, vol. 51, no. 11, pp. 5853–5857, 2010.

[2] R. F. Spaide, M. Goldbaum, D. W. K. Wong, K. C. Tang, and T. Iida, “Serous detachment of the retina,” Retina, vol. 23, no. 6, pp. 820–846, 2003, quiz 895–826.

[3] D. R. Guyer, L. A. Yannuzzi, J. S. Slakter, J. A. Sorenson, A. Ho, and D. Orlock, “Digital indocyanine green videoangiography of central serous chorioretinopathy,” Archives of Ophthalmology, vol. 112, no. 8, pp. 1057–1062, 1994.

[4] J. D. Gass, “Pathogenesis of disciform detachment of the neuroepithelium,” American Journal of Ophthalmology, vol. 63, no. 3, Supplement, pp. 1–139, 1967.

[5] A. Ross, A. H. Ross, and Q. Mohamed, “Review and update of central serous chorioretinopathy,” Current Opinion in Ophthalmology, vol. 22, no. 3, pp. 166–173, 2011.

[6] R. Haimovici, S. Koh, D. R. Gagnon, T. Lehrfeld, and S. Wellik, “Risk factors for central serous chorioretinopathy: a case-control study,” Ophthalmology, vol. 111, no. 2, pp. 244–249, 2004.

[7] A. S. Kitzmann, J. S. Pulido, N. N. Diehl, D. O. Hodge, and J. P. Burke, “The incidence of central serous choriotretinopathy in Olmsted County, Minnesota, 1980–2002,” Ophthalmology, vol. 115, no. 1, pp. 169–173, 2008.

[8] R. F. Spaide, L. Campeas, A. Haas et al., “Central serous choriotretinopathy in younger and older adults,” Ophthalmology, vol. 103, no. 12, pp. 2070–2080, 1996, discussion 2079–2080.

[9] J. Castro-Correia, M. F. Coutinho, V. Rosas, and J. Maia, “Long-term follow-up of central serous retinopathy in 150 patients,” Documenta Ophthalmologica, vol. 81, no. 4, pp. 379–386, 1992.

[10] C. M. Gilbert, S. L. Owens, P. D. Smith, and S. L. Fine, “Long-term follow-up of central serous choriotretinopathy,” The British Journal of Ophthalmology, vol. 68, no. 11, pp. 815–820, 1984.

[11] G. Bennett, “Central serous retinopathy,” The British Journal of Ophthalmology, vol. 39, no. 10, pp. 605–618, 1955.

[12] R. Haimovici, E. S. Gragoudas, J. S. Duker, R. N. Sjaarda, and D. Elliott, “Central serous choriotretinopathy associated with inhaled or intranasal corticosteroids,” Ophthalmology, vol. 104, no. 10, pp. 1653–1660, 1997.

[13] G. S. Gelber and H. Schatz, “Loss of vision due to central serous choriotretinopathy following psychological stress,” The American Journal of Psychiatry, vol. 144, no. 1, pp. 46–50, 1987.

[14] L. A. Yannuzzi, “Type A behavior and central serous choriotretinopathy,” Retina, vol. 32, Supplement 1, p. 709, 2012.

[15] L. C. Chumbley and R. N. Frank, “Central serous retinopathy and pregnancy,” American Journal of Ophthalmology, vol. 77, no. 2, pp. 158–160, 1974.

[16] E. A. Bouzas, M. H. Scott, G. Mastorakos, G. P. Chrousos, and M. I. Kaiser-Kupfer, “Central serous choriotretinopathy in endogenous hypercortisolism,” Archives of Ophthalmology, vol. 111, no. 9, pp. 1229–1233, 1993.

[17] F. W. Fraunfelder and F. T. Fraunfelder, “Central serous choriotretinopathy associated with sildenafil,” Retina, vol. 28, no. 4, pp. 606–609, 2008.

[18] P. Kloos, I. Laube, and A. Thoelen, “Obstructive sleep apnea in patients with central serous choriotretinopathy,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 9, pp. 1225–1228, 2008.

**Figure 16:** Review of treatment options in patients with central serous chorioretinopathy (CSCR). CNV: choroidal neovascularization; MR: mineralocorticoid; PDT: photodynamic therapy; VEGF: vascular endothelial growth factor.
L. Cotticelli, M. Borrelli, A. C. D’alessio et al., “Central serous chorioretinopathy and helicobacter pylori,” European Journal of Ophthalmology, vol. 16, no. 2, pp. 274–278, 2018.

H. Schatz, M. D. Osterloh, H. R. McDonald, and R. N. Johnson, “Development of retinal vascular leakage and cystoid macular oedema secondary to central serous chorioretinopathy,” The British Journal of Ophthalmology, vol. 77, no. 11, pp. 744–746, 1993.

F. B. Aggio, L. Roisman, G. B. Melo, D. Lavinsky, J. A. Cardillo, and M. E. Farah, “Clinical factors related to visual outcome in central serous chorioretinopathy,” Retina, vol. 30, no. 7, pp. 1128–1134, 2010.

K. Yamada, S. Hayasaka, and T. Setogawa, “Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit,” Ophthalmologica, vol. 205, no. 2, pp. 69–76, 1992.

M. Wang, I. C. Munch, P. W. Hasler, C. Prunte, and M. Larsen, “Central serous chorioretinopathy,” Acta Ophthalmologica, vol. 86, no. 2, pp. 126–145, 2008.

N. Kitaya, T. Nagaoka, T. Hikichi et al., “Features of abnormal chorioidal circulation in central serous chorioretinopathy,” The British Journal of Ophthalmology, vol. 87, no. 6, pp. 709–712, 2003.

R. F. Spaide, L. Hall, A. Haas et al., “Indocyanine green videoangiography of older patients with central serous chorioretinopathy,” Retina, vol. 16, no. 3, pp. 203–213, 1996.

F. C. Delori, C. K. Dorey, G. Staurenghi, O. Ar登, D. G. Goger, and J. J. Weiter, “In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics,” Investigative Ophthalmology & Visual Science, vol. 36, no. 3, pp. 718–729, 1995.

G. E. Eldred and M. L. Katz, “Fluorophores of the human retinal pigment epithelium: separation and spectral characterization,” Experimental Eye Research, vol. 47, no. 1, pp. 71–86, 1988.

R. F. Spaide and J. M. Klancnik Jr., “Fundus autofluorescence and central serous chorioretinopathy,” Ophthalmology, vol. 112, no. 5, pp. 825–833, 2005.

Y. Imamura, T. Fujiwara, and R. F. Spaide, “Fundus autofluorescence and visual acuity in central serous chorioretinopathy,” Ophthalmology, vol. 118, no. 4, pp. 700–705, 2011.

Y. Imamura, T. Fujiwara, R. Margolis, and R. F. Spaide, “Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy,” Retina, vol. 29, no. 10, pp. 1469–1473, 2009.

D. J. Warrow, Q. V. Hoang, and K. B. Freund, “Pachychoroid pigment epitheliopathy,” Retina, vol. 33, no. 8, pp. 1659–1672, 2013.

O. Gal-Or, K. K. Dansingani, D. Sebrow, R. Dolz-Marco, and K. B. Freund, “Inner choroidal flow signal attenuation in pachychoroid DISEASE,” Retina, vol. 38, no. 10, pp. 1984–1992, 2018.

S. Akkaya, “Spectrum of pachychoroid diseases,” International Ophthalmology, vol. 38, no. 5, pp. 2239–2246, 2018.

J. Siedlecki, B. Schworn, and S. G. Priglinger, “The pachychoroid disease spectrum—and the need for a uniform classification system,” Ophthalmol Retina, vol. 3, no. 12, pp. 1013–1015, 2019.

Y. Jia, S. T. Bailey, D. J. Wilson et al., “Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration,” Ophthalmology, vol. 121, no. 7, pp. 1435–1444, 2014.

M. Q.-E. Maftouhi, A. El Maftouhi, and C. M. Eandi, “Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography,” American Journal of Ophthalmology, vol. 160, no. 3, pp. 581–587.e1, 2015.

R. F. Spaide, J. M. Klancnik Jr., and M. J. Cooney, “Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography,” JAMA Ophthalmology, vol. 133, no. 1, pp. 45–50, 2015.

R. Brancato, A. Sicaldone, A. Pece, G. Coscas, and M. Binaghi, “Eight-year follow-up of central serous chorioretinopathy with and without laser treatment,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 225, no. 3, pp. 166–168, 1987.

L. Ficker, G. Vafidis, A. While, and P. Leaver, “Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy,” The British Journal of Ophthalmology, vol. 72, no. 11, pp. 829–834, 1988.

J. W. Lim, S. W. Kang, Y. T. Kim, S. E. Chung, and S. W. Lee, “Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy,” The British Journal of Ophthalmology, vol. 95, no. 4, pp. 514–517, 2011.

G. Quin, G. Liew, I. V. Ho, M. Gillesy, and S. Fraser-Bell, “Diagnosis and interventions for central serous chorioretinopathy: review and update,” Clinical & Experimental Ophthalmology, vol. 41, no. 2, pp. 187–200, 2013.

P. Iacono, M. B. Parodi, B. Falcomat&iuml, and F. Bandello, “Central serous chorioretinopathy treatments: a mini review,” Ophthalmic Research, vol. 55, no. 2, pp. 76–83, 2015.

A. Negi and M. F. Marmor, “Experimental serous retinal detachment and focal pigment epithelial damage,” Archives of Ophthalmology, vol. 102, no. 3, pp. 445–449, 1984.

E. Burumcek, A. Mudun, S. Karacorlu, and M. O. Arslan, “Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up,” Ophthalmology, vol. 104, no. 4, pp. 616–622, 1997.

P. Scholz, L. Altay, and S. Fauser, “A review of subthreshold micropulse laser for treatment of macular disorders,” Advances in Therapy, vol. 34, no. 7, pp. 1528–1555, 2017.

P. Lanzetta, F. Furlan, L. Morgante, D. Veritti, and F. Bandello, “Nonvisible subthreshold micropulse diode laser (8 10 nm) treatment of central serous chorioretinopathy. A pilot study,” European Journal of Ophthalmology, vol. 18, no. 6, pp. 934–940, 2018.

F. Bandello, P. Lanzetta, F. Furlan, and A. Polito, “Non-visible subthreshold micropulse diode laser treatment of idiopathic central serous chorioretinopathy. A pilot study,” Investigative Ophthalmology & Visual Science, vol. 44, no. 5, p. 4858, 2003.

L. A. Yannuzzi, J. S. Slakter, N. E. Gross et al., “Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study,” Retina, vol. 23, no. 3, pp. 288–298, 2003.

M. D. Ober, L. A. Yannuzzi, D. V. Do et al., “Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy,” Ophthalmology, vol. 112, no. 12, pp. 2088–2094, 2005.
[50] J. I. Lim, A. R. Glassman, L. P. Aiello, U. Chakravarthy, C. J. Flaxel, and R. F. Spaide, “Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy,” Ophthalmology, vol. 121, no. 5, pp. 1073–1078, 2014.

[51] T. Y. Y. Lai, W.-M. Chan, H. Li, R. Y. K. Lai, D. T. L. Liu, and D. S. C. Lam, “Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study,” The British Journal of Ophthalmology, vol. 90, no. 7, pp. 869–874, 2006.

[52] M.-W. Zhao, P. Zhou, H.-X. Xiao et al., “Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin,” Retina, vol. 29, no. 8, pp. 1155–1161, 2009.

[53] W.-M. Chan, T. Y. Y. Lai, R. Y. K. Lai, D. T. L. Liu, and D. S. C. Lam, “Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy: One-Year Results of a Randomized Controlled Trial,” Ophthalmology, vol. 115, no. 10, pp. 1756–1765, 2008.

[54] M. Zhao, I. Célérier, E. Bousquet et al., “Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy,” The Journal of Clinical Investigation, vol. 122, no. 7, pp. 2672–2679, 2012.

[55] A. Struthers, H. Krum, and G. H. Williams, “A comparison of the aldosterone-blocking agents eplerenone and spironolactone,” Clinical Cardiology, vol. 31, no. 4, pp. 153–158, 2008.

[56] A. Karim, “Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability,” Drug Metabolism Reviews, vol. 8, no. 1, pp. 151–188, 2008.

[57] E. Rahimy, J. D. Pitcher III, M. S. Fineman, C. Prunte, and J. Hsu, “Oral mineralocorticoid receptor antagonists for the treatment of CSC,” Retinal Physicians, vol. 13, pp. 22–27, 2016.

[58] M. de Gasparo, U. Joss, H. P. Ramjoué et al., “Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro,” The Journal of Pharmacology and Experimental Therapeutics, vol. 240, no. 2, pp. 650–656, 1987.

[59] E. Bousquet, T. Beydoun, M. Zhao, L. Hassan, O. Offret, and F. Behar-Cohen, “Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study,” Retina, vol. 33, no. 10, pp. 2096–2102, 2013.

[60] E. Bousquet, T. Beydoun, P. R. Rothschild et al., “Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study,” Retina, vol. 35, no. 12, pp. 2505–2515, 2015.

[61] T. R. Herold, K. Prause, A. Wolf, W. J. Mayer, and M. W. Ulbig, “Spironolactone in the treatment of central serous chorioretinopathy - a case series,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 12, pp. 1985–1991, 2014.

[62] J. W. Lim, M. U. Kim, and M. C. Shin, “Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy,” Retina, vol. 30, no. 9, pp. 1465–1471, 2010.

[63] O. Artunay, E. Yuzbasioğlu, R. Rasier, A. Sengul, and H. Bahcecioglu, “Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study,” Current Eye Research, vol. 35, no. 2, pp. 91–98, 2010.